Evidence map›Paper›PMID 40430928›Full record

ReviewPharmaceutics2025

Agents for Fluorescence-Guided Glioblastoma Surgery.

Eleni Romeo, Andreas G Tzakos, Timothy Crook, Nelofer Syed, Spyridon Voulgaris, George A Alexiou

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eleni RomeoNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.
Andreas G TzakosSection of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0001-6391-0288
Timothy CrookDepartment of Brain Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Nelofer SyedDepartment of Brain Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.ORCID 0000-0003-1104-5805
Spyridon VoulgarisNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.
George A AlexiouNeurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.ORCID 0000-0003-0257-4481

Funding

RESEARCH-CREATE-INNOVATE TAEDK-06189/ Τ2EDK-0326
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid progression and a median survival of no more than 12-18 months. Fluorescence-guided surgery is crucial, as it allows for tumor visualization and aids in its complete removal, which is essential for improving survival rates. We conducted a literature review to identify fluorescent agents that have been utilized in the removal of GBM and to assess their benefits in achieving maximum tumor resection. Our analysis focuses on their advantages, limitations, and potential impact on improving surgical precision and patient outcomes. We searched the PubMed database for studies published on fluorescence-guided resection of GBM and evaluated the utility of each agent in terms of outcomes, gross total resection (GTR), and their sensitivity and specificity for the tumor. The literature review revealed that the three agents successfully utilized are 5-aminolevulinic acid (5-ALA), sodium fluorescein, and indocyanine green. In addition to these, a variety of dyes have been investigated in studies, including peptides, lipids, and nanosystems, which appear to be very promising. To date, numerous fluorescent agents have been proposed for the surgical resection of GBM. However, 5-aminolevulinic acid (5-ALA) remains the only agent widely adopted in clinical practice, as its safety and efficacy have been well-established. Further clinical trials and studies are necessary to assess the utility, effectiveness, and potential advantages of emerging fluorescent dyes in enhancing GBM resection and improving patient outcomes.

Indexed as

5-ALAfluoresceinfluorescence dyesfluorophoresglioblastomaindocyanine greenluminescent agents

Identifiers

PMID40430928
PMCPMC12115318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.